Related Experiment Video
Updated: May 23, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
[Antifungal treatment options in the critically ill patient]
Rafael Zaragoza1, Javier Pemán
1Servicio de Medicina Intensiva, Hospital Universitario Dr. Peset, Valencia, España.
Abstract:
Invasive fungal infections, especially in the critical care setting, have become an excellent target for prophylactic, empiric, and pre-emptive therapy interventions due to their associated high morbidity, mortality rate, increased incidence, and healthcare costs. For these reasons, new studies and laboratory tests have been developed over the last few years in order to formulate an early therapeutic intervention strategy in an attempt to reduce the high mortality rate associated with these infections. In recent years, evidence-based studies have shown the roles that the new antifungal drugs play in the treatment of invasive mycosis in seriously ill and complex patients, although data from critically ill patients are more limited. New antifungal agents have been analyzed in different clinical situations in critical care units, and the increasing number of non-Candida albicans species suggest that the application of early echinocandin therapy in critically ill patients with invasive candidiasis is a good option. Voriconazole should be recommended for invasive aspergillosis as a first line option.
Insights
New antifungal therapies offer improved outcomes for invasive fungal infections in critically ill patients. Early echinocandin use for candidiasis and voriconazole for aspergillosis are recommended.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Mycology
Context:
- Invasive fungal infections (IFIs) pose significant challenges in critical care settings.
- High morbidity, mortality, incidence, and healthcare costs necessitate effective interventions.
- Limited data exist on antifungal drug efficacy specifically in critically ill populations.
Purpose:
- To review the role of new antifungal drugs in treating invasive mycosis in critically ill patients.
- To evaluate therapeutic strategies for early intervention against IFIs.
- To provide evidence-based recommendations for antifungal use in intensive care units.
Summary:
- New antifungal agents are being analyzed for various clinical situations in critical care.
- Evidence suggests early echinocandin therapy is a viable option for invasive candidiasis, especially with non-Candida albicans species.
- Voriconazole is recommended as a first-line treatment for invasive aspergillosis.
Impact:
- Optimizing antifungal strategies can reduce mortality associated with IFIs in critical care.
- Early and targeted antifungal therapy can improve patient outcomes and lower healthcare costs.
- This review supports evidence-based decision-making for managing IFIs in complex, critically ill patients.
Related Concept Videos
Antifungal Agents
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Endocarditis III: Medical Management
Fungal Phylum Microsporidia
Acute Pyelonephritis II: Diagnostic Studies and Management
Endocarditis IV: Nursing Management
